Explore

Rapid Read Rapid Read
FDA Approves Pluvicto for Expanded Use in Metastatic Prostate Cancer

FDA Approves Pluvicto for Expanded Use in Metastatic Prostate Cancer

The U.S. Food and Drug Administration (FDA) has approved Pluvicto, a radioligand therapy developed by Novartis, for use in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC). This approval is based on the Phase III PSMAddition trial, which demonstrated that Pluvicto, in combination with standard care, significantly reduces the risk of disease progression or death. The therapy is now available for use across all stages of PSMA-positive metastatic prostate cancer, nearly doubling the eligible patient population. This marks a significant advancement in the treatment landscape for mHSPC, offering a new precision approach for early intervention.
Trendline Trendline
Oral Wegovy: A New Option for Weight Management with Considerations

Oral Wegovy: A New Option for Weight Management with Considerations

Oral Wegovy: A New Option for Weight Management with Considerations
Trendline Trendline
HexemBio Secures $10.4M Seed Funding to Advance Blood Stem Cell Rejuvenation

HexemBio Secures $10.4M Seed Funding to Advance Blood Stem Cell Rejuvenation

HexemBio Secures $10.4M Seed Funding to Advance Blood Stem Cell Rejuvenation
Rapid Read Rapid Read
Study Reveals Genetic Basis for Pathogenicity in MeCP2 Mutations

Study Reveals Genetic Basis for Pathogenicity in MeCP2 Mutations

A recent study has uncovered the genetic basis for why certain C-terminal frameshift deletions in the MECP2 gene cause Rett syndrome (RTT) in some individuals but not in others. The research highlights that the presence of a -PPX motif at the C-terminus of the truncated protein is a key determinant of pathogenicity. The study utilized mouse models and adenine base editing technology to demonstrate that altering the C-terminal sequence can prevent the loss of MeCP2 protein, offering potential therapeutic strategies for RTT patients.
Rapid Read Rapid Read
New Drug Daraxonrasib Shows Promise in Extending Survival for Pancreatic Cancer Patients

New Drug Daraxonrasib Shows Promise in Extending Survival for Pancreatic Cancer Patients

Daraxonrasib, a new drug targeting RAS proteins, has shown promising results in clinical trials for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The drug, part of a new class of RAS(ON) inhibitors, effectively silences RAS proteins, which are crucial in tumor growth and spread. In trials, daraxonrasib doubled the median survival time for patients whose cancer had stopped responding to chemotherapy, from 6.7 to 13.2 months. This development is seen as a breakthrough in treating one of the most challenging cancers, offering hope for improved outcomes and quality of life for patients.
Trendline Trendline
FDA Approves Moderna's mFLUSIVA, Strengthening Its Position in mRNA Vaccine Market

FDA Approves Moderna's mFLUSIVA, Strengthening Its Position in mRNA Vaccine Market

FDA Approves Moderna's mFLUSIVA, Strengthening Its Position in mRNA Vaccine Market
Trendline Trendline
Sanofi Faces Drug Shortage for Pompe Disease Amid Manufacturing Issues

Sanofi Faces Drug Shortage for Pompe Disease Amid Manufacturing Issues

Sanofi Faces Drug Shortage for Pompe Disease Amid Manufacturing Issues
Rapid Read Rapid Read
FDA Approves Moderna's mRNA Flu Vaccine mFlusiva for Adults 50 and Older

FDA Approves Moderna's mRNA Flu Vaccine mFlusiva for Adults 50 and Older

The U.S. Food and Drug Administration (FDA) has approved Moderna's mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older. This approval marks a significant advancement in influenza vaccine development, leveraging mRNA technology to potentially shorten production times compared to traditional vaccines. The vaccine has received full approval for individuals aged 50 to 64, while those aged 65 and older have been granted accelerated approval, pending further clinical trials. The decision follows positive results from late-stage clinical trials involving over 40,000 participants across 11 countries, demonstrating mFlusiva's efficacy. The vaccine is expected to be available for the upcoming flu season, although its distribution may be impacted by the lack of a formal recommendation from the CDC's Advisory Committee on Immunization Practices (ACIP).
Vox Vox
The strange reason flu shots have been so hard to improve

The strange reason flu shots have been so hard to improve

America finally has an mRNA flu shot. Now comes the fight to actually use it.
Rapid Read Rapid Read
US Approves First mRNA Flu Vaccine Amidst Research Funding Shift

US Approves First mRNA Flu Vaccine Amidst Research Funding Shift

The United States has approved its first mRNA-based flu vaccine, mFLUSIVA, developed by Moderna. This approval by the Food and Drug Administration (FDA) is a milestone in modernizing flu vaccine development. The vaccine is targeted at adults aged 50 and older and is expected to be available for the 2026-2027 flu season. The approval comes a year after the Department of Health and Human Services (HHS) ceased funding for mRNA vaccine research, citing a shift towards alternative solutions. Despite this, the vaccine's approval is seen as a significant step forward in public health.
Rapid Read Rapid Read
FDA Approves Moderna's mRNA Flu Vaccine for Older Adults, Offering New Protection

FDA Approves Moderna's mRNA Flu Vaccine for Older Adults, Offering New Protection

The Food and Drug Administration (FDA) has approved Moderna's mRNA-based flu vaccine, mFlusiva, marking a significant advancement in flu prevention for adults aged 50 and older. This approval is the first of its kind for a non-COVID-related mRNA vaccine in the United States. The vaccine is initially approved for individuals aged 50 to 64, with further studies planned for those over 65. Clinical trials demonstrated that mFlusiva is 26.6% more effective than traditional flu vaccines. Moderna plans to make the vaccine available at select retailers soon, as other flu vaccines are already arriving in pharmacies for the upcoming vaccination season.
Trendline Trendline
FDA Approval of Oral Wegovy Raises Questions on Weight Loss and Muscle Preservation

FDA Approval of Oral Wegovy Raises Questions on Weight Loss and Muscle Preservation

FDA Approval of Oral Wegovy Raises Questions on Weight Loss and Muscle Preservation